These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 21740359)

  • 1. Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.
    Kaur B; Chiocca EA; Cripe TP
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1842-51. PubMed ID: 21740359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent clinical experience with oncolytic viruses.
    Donnelly OG; Errington-Mais F; Prestwich R; Harrington K; Pandha H; Vile R; Melcher AA
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1834-41. PubMed ID: 21740364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.
    Bernstock JD; Hoffman SE; Chen JA; Gupta S; Kappel AD; Smith TR; Chiocca EA
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34204248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine.
    Li QX; Liu G; Zhang X
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1773-85. PubMed ID: 21740353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular basis of herpesviruses as oncolytic agents.
    Menotti L; Campadelli-Fiume G; Nanni P; Lollini PL; De Giovanni C
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1795-803. PubMed ID: 21740356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of oncolytic viruses in China.
    Liang M
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1852-7. PubMed ID: 21740357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
    Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic HSV: Underpinnings of Tumor Susceptibility.
    Kangas C; Krawczyk E; He B
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].
    Hao M; Huang C; Xia N
    Bing Du Xue Bao; 2016 Jul; 32(4):516-22. PubMed ID: 29996042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progess on research of herpes simplex virus type 1 mutants for cancer therapy].
    Long Y; Mi Y; Li Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Dec; 25(6):1446-9. PubMed ID: 19166228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of non-replicative and oncolytic replication-selective HSV vectors.
    Epstein AL; Rabkin SD
    Trends Mol Med; 2024 Aug; 30(8):781-794. PubMed ID: 38886138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Virotherapy by HSV.
    Watanabe D; Goshima F
    Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advance in herpes simplex viruses for cancer therapy.
    Liu S; Dai M; You L; Zhao Y
    Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
    Ghonime MG; Cassady KA
    Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ReVOLT: radiation-enhanced viral oncolytic therapy.
    Advani SJ; Mezhir JJ; Roizman B; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):637-46. PubMed ID: 17011442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
    Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
    Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
    Uche IK; Kousoulas KG; Rider PJF
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.
    Fu X; Rivera A; Tao L; Zhang X
    Mol Ther; 2012 Oct; 20(10):1871-81. PubMed ID: 22692498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
    Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
    Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.